spin ph pba news trade
White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign
Most Gulf markets gain on rising oilA majority of UK businesses expect a positive start to 2025, according to two economic confidence surveys which show managers planning for growth after a challenging period for the economy. About 70% of UK businesses expect their turnover to increase over the next year, up from 62% in December 2023. Meanwhile, 73% are confident of greater profitability, according to research from Lloyds bank. Hann-Ju Ho, a senior economist at Lloyds, said: “It is exciting to see that businesses have ambitious plans for next year and are confident of growth. Overall, businesses have responded well to the changing external environment. While the economic outlook has been challenging, the steps firms are taking to grow should put them in a strong position for success in 2025.” The survey by the high street bank, which polls 1,200 businesses monthly and claims to provide early signals about UK economic trends, was mirrored by research into expectations in the financial sector, a key driver of the UK economy. Seven in 10 financial services bosses said they are confident that the government’s plans will drive growth and competitiveness in the sector during 2025, according to data collated by the accounting group KPMG. The quarterly poll, which tracks sentiment among more than 160 senior financial services executives, found that 68% are confident that the chancellor’s plans to “regulate for growth” and launch a financial services competitiveness strategy in the spring will help to attract foreign financial services investment. Last month, during her Mansion House speech, Rachel Reeves argued that the UK has been “ regulating for risk, but not regulating for growth ” as she outlined a reboot of the rules governing Britain’s “crown jewel” financial services industry. “While it was right that successive governments made regulatory changes after the global financial crisis, to ensure that regulation kept pace with the global economy of the time, it is important that we learn the lessons of the past,” the chancellor said. “These changes have resulted in a system which sought to eliminate risk-taking. That has gone too far and, in places, it has had unintended consequences which we must now address.” Karim Haji, global and UK head of financial services at KPMG, said: “Financial services is the backbone of the UK economy, so it’s encouraging to see leaders go into the new year with optimism about the government’s growth plans for the sector. “However, there are still concerns related to the impact of the budget on growth in financial services. In the first half of 2025 the sector will want to see more details on the government’s competitiveness strategy to really understand how the chancellor is proposing to work with them on strengthening the UK’s attractiveness as a global financial centre .” Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion While these two surveys appear to suggest that some UK businesses are more optimistic than widely thought, they do appear to contradict other recent business polls. Last week, the Confederation of British Industry’s growth indicator survey set out how British companies are predicting a sharp fall in business activity in the new year, with firms preparing to cut down on hiring and reduce output over the next three months. Separate data also published last week suggested that retailers face a further blow in the new year, with consumer spending forecasts falling by six points, according to the British Retail Consortium. “If these expectations are realised, retailers could find themselves facing a new year spending squeeze just as they unveil their January sales,” said the BRC chief executive, Helen Dickinson. The Bank of England said this month that it expected the latest data to show that UK growth flatlined in the final three months of 2024, after inflation rose to an eight-month high of 2.6%.
French government toppled in deepening political crisisJanux Therapeutics, Inc. ( NASDAQ:JANX – Get Free Report ) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at $12,196,264.26. This represents a 10.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link . David Alan Campbell also recently made the following trade(s): Janux Therapeutics Stock Down 1.9 % JANX stock opened at $54.10 on Friday. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71. The firm’s 50-day moving average is $54.43 and its 200 day moving average is $47.43. Institutional Investors Weigh In On Janux Therapeutics Several hedge funds have recently made changes to their positions in JANX. Charles Schwab Investment Management Inc. increased its stake in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after buying an additional 156,675 shares during the period. Ally Bridge Group NY LLC purchased a new position in Janux Therapeutics during the 3rd quarter valued at about $4,943,000. Algert Global LLC bought a new stake in shares of Janux Therapeutics in the 3rd quarter valued at about $1,112,000. FMR LLC raised its holdings in shares of Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after purchasing an additional 47,075 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics in the 3rd quarter worth approximately $940,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analyst Weigh In Several equities analysts have recently commented on the stock. Scotiabank boosted their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. Stifel Nicolaus raised their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. BTIG Research boosted their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Finally, Leerink Partners lifted their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Buy” and an average target price of $89.90. Get Our Latest Stock Report on Janux Therapeutics Janux Therapeutics Company Profile ( Get Free Report ) Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Further Reading Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .New era in amphibian biology November 26, 2024 Institute of Science and Technology Austria Amphibians hold a significant place in evolution, representing the transition from aquatic to terrestrial lifestyles. They are crucial for understanding the brain and spinal cord of tetrapods -- animals with four limbs, including humans. A group of scientists now shows how harmless viruses can be used to illuminate the development of the frog nervous system. Facebook Twitter Pinterest LinkedIN Email Amphibians hold a significant place in evolution, representing the transition from aquatic to terrestrial lifestyles. They are crucial for understanding the brain and spinal cord of tetrapods -- animals with four limbs, including humans. A group of scientists led by a team at the Institute of Science and Technology Austria (ISTA) now shows how harmless viruses can be used to illuminate the development of the frog nervous system. The results have now been published in Developmental Cell . Virus. When you hear the word, you probably shudder. But not all viruses are bad or cause disease. Some are even used for therapeutic applications or vaccination. In basic research, they are often employed to infect certain cells, genetically modify them, or visualize neurons in the organism's central nervous system (CNS) -- the command center made up of the brain, spinal cord, and nerves. The highlighting process now finally works in amphibians. This has been shown in a new study by an international EDGE consortium jointly led by the Sweeney Lab at the Institute of Science and Technology Austria (ISTA) and the Tosches Lab at Columbia University. The researchers established a new technique that uses adeno-associated viruses (AAVs) to track a frog's nervous system throughout its metamorphosis -- a developmental transition from the early tadpole stages to its adult form. A breakthrough that can help usher amphibian neurobiology into a new era. Swimming vs. walking David Vijatovic and Lora Sweeney enter a laboratory full of water tanks. Vijatovic taps on one of them. Inside, a small mottled greenish-brown African clawed frog (Xenopus laevis) appears. Its limbs are prominent, gracefully maneuvering and gripping its surroundings. In another tank, tadpoles are swirling around using simple swimming motions. It is remarkable to think that one transforms into the other. "Frogs undergo metamorphosis," Sweeney says, "making them a great model organism for studying the transition between two movement modes -- swimming and walking." A frog's development spans over 12 to 16 weeks, giving scientists time to study each stage. During these weeks, a frog embryo develops to a young tadpole, a tadpole with two legs, and a young froglet with four legs before reaching the adult stage. "By looking at the several stages of development, we can investigate these locomotive behaviors and the underlying changes in the nervous system," Vijatovic adds. Just like an electrical circuit: how frogs are wired An organism's nervous system is referred to as the neural circuit because it resembles an electrical circuit. "Nerve cells (neurons) are connected to other neurons, transmitting electrical information. How we behave, what we sense, and how we interact with the world are the product of the way our neurons communicate with each other within these circuits," explains Sweeney. The critical piece is how the circuit is wired. We know that neurons are connected but which neuron connects to which? Which other cells does a single cell talk to, and what messages does it convey? To know more about this wiring, researchers have been using viruses, proven to be a powerful tool. Adeno-associated viruses (AAVs) are ideal in that regard. They are non-pathogenic while being able to infect a wide range of cell types, including neurons. AAVs can be modified to glow in bright green fluorescent colors under the microscope as they travel along neurons, whether in retrograde (backward, from the synapse toward the cell body) or anterograde (forward, from the cell body toward the synapse). In other words, AAVs can be used to illuminate the neural circuit from the broadcasting end to the receiving end or vice-versa. "This is a common technique used in neuroscience, especially in well-studied organisms like mice. For amphibians, it was thought that it could not be done," says Vijatovic. That was the general belief until now. The power of scientific collaboration To make AAV labeling work in amphibians, Sweeney and Vijatovic joined forces with an international team of scientists from Maria Tosches' group at Columbia University, where the study's other two co-first authors Eliza Jaeger and Astrid Deryckere are based. The consortium also included researchers from Tel Aviv University, the University of Utah, the Scripps Research Institute, and the California Institute of Technology. The researchers put their heads together, drew expertise from each other, visited conferences, had countless Zoom calls, and came up with different perspectives and ideas. "When you start researching an organism that is not yet well understood, it is great to have a community where you can share information," says Sweeney. They screened existing AAVs to find what was suitable for amphibians and optimized the infecting strategy eventually developing a "how-to guide" for frogs and newts. Vijatovic summarizes his PhD journey, "We started with young tadpoles, made our way to older tadpoles, and finally moved to juvenile and then adult frogs as well as adult newts. We tailored the tool to each life stage." Comparing frogs to humans: what this research says about us With this new technique, the scientists managed to apply AAVs for tracing neuron connections in amphibians. This will help them find out more about how the amphibian brain compares to that of mammals. Besides that, the new approach also opens doors to further analyzing neuronal development. With some of the screened AAV variants, the researchers can label progenitor cells at a specific point in time during the circuit's development and follow them to see what neurons they become. "This way, we can resolve the whole circuit by its development, see how it changes over time, and how the whole nervous system is built," Sweeney says. Although amphibians and mammals last shared a common ancestor about 360 million years ago, they share common traits. "By comparing the details of a frog's nervous system to a human's, we can see what we don't have and what we have," Sweeney continues. This knowledge can help us understand how the human nervous system became specialized over time. "The better we understand the basic building blocks of the nervous system, the more we understand how we can replace them during disease and injury." Story Source: Materials provided by Institute of Science and Technology Austria . Note: Content may be edited for style and length. Journal Reference : Cite This Page :None
Services board starts budget talks, pitches 9.82% increase
Pete Hegseth's mother says The New York Times made 'threats' by asking her to comment on a storyDrought, fires and deforestation battered Amazon rainforest in 2024
